Search research articles
Contact Us
Filters
Showing results (31-40 of 48) with videos related to
Page
of 5
Sort By:
Journal of Autoimmunity
|
December 3, 2014
Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells
Charles J M Bell, Yongliang Sun, Urszula M Nowak, et al.
Mabs
|
March 18, 2016
XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer
Juergen M Schanzer, Katharina Wartha, Ekkehard Moessner, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
February 18, 2018
The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo
Adam Palazzo, Sylvia Herter, Laura Grosmaire, et al.
Oncoimmunology
|
April 9, 2016
Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor
Jens Schreiner, Daniela S Thommen, Petra Herzig, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
February 12, 2026
PD1-IL2v expands and induces effector CD8<sup>+</sup> TILs, but not Tregs, in the BCG treated orthotopic non-muscle invasive bladder cancer model
Irene Locatelli, Marco Lorenzoni, Chiara Venegoni, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 11, 2015
Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti-Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis
Peter Laverman, Tessa van der Geest, Samantha Y A Terry, et al.
Molecular Cancer Therapeutics
|
July 23, 2013
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models
Sylvia Herter, Frank Herting, Olaf Mundigl, et al.
Med (New York, N.Y.)
|
April 9, 2024
Myeloid-T cell interplay and cell state transitions associated with checkpoint inhibitor response in melanoma
Ramona Schlenker, Petra C Schwalie, Steffen Dettling, et al.
Science Translational Medicine
|
March 13, 2020
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
Maud Mayoux, Andreas Roller, Vesna Pulko, et al.
Archives of Biochemistry and Biophysics
|
April 3, 2012
Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition
Rebecca Croasdale, Katharina Wartha, Juergen M Schanzer, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 48) with videos related to
Sort By:
Page
of 5
Journal of Autoimmunity
|
December 3, 2014
Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells
Charles J M Bell, Yongliang Sun, Urszula M Nowak, et al.
Mabs
|
March 18, 2016
XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer
Juergen M Schanzer, Katharina Wartha, Ekkehard Moessner, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
February 18, 2018
The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo
Adam Palazzo, Sylvia Herter, Laura Grosmaire, et al.
Oncoimmunology
|
April 9, 2016
Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor
Jens Schreiner, Daniela S Thommen, Petra Herzig, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
February 12, 2026
PD1-IL2v expands and induces effector CD8<sup>+</sup> TILs, but not Tregs, in the BCG treated orthotopic non-muscle invasive bladder cancer model
Irene Locatelli, Marco Lorenzoni, Chiara Venegoni, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 11, 2015
Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti-Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis
Peter Laverman, Tessa van der Geest, Samantha Y A Terry, et al.
Molecular Cancer Therapeutics
|
July 23, 2013
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models
Sylvia Herter, Frank Herting, Olaf Mundigl, et al.
Med (New York, N.Y.)
|
April 9, 2024
Myeloid-T cell interplay and cell state transitions associated with checkpoint inhibitor response in melanoma
Ramona Schlenker, Petra C Schwalie, Steffen Dettling, et al.
Science Translational Medicine
|
March 13, 2020
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
Maud Mayoux, Andreas Roller, Vesna Pulko, et al.
Archives of Biochemistry and Biophysics
|
April 3, 2012
Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition
Rebecca Croasdale, Katharina Wartha, Juergen M Schanzer, et al.
Page
of 5